Strata Oncology

Executive Summary

Strata Oncology is a precision oncology company developing advanced algorithmic biomarkers powered by AI and machine learning to predict patient responses to immunotherapies and antibody-drug conjugates (ADCs). Founded in 2016 and headquartered in Ann Arbor, Michigan, the company's platform analyzes tumor biology from patient samples to guide treatment decisions, aiming to ensure each patient receives the most effective therapy. By addressing the limitations of existing biomarkers such as PD-L1, Strata's predictive diagnostics have the potential to improve outcomes, reduce healthcare costs, and enable more personalized cancer care. As a private company, Strata has not disclosed funding details but is positioned to capitalize on the growing demand for precision medicine solutions in oncology. Its focus on AI-driven biomarker development aligns with industry trends toward data-driven therapeutic selection, and the company may pursue partnerships with pharmaceutical firms or further clinical validation studies.

Upcoming Catalysts (preview)

• Q3 2026Publication of clinical validation data for algorithmic biomarkers70% success
• Q4 2026Strategic partnership with a pharmaceutical or biotech company60% success
• Q1 2027Series B or later funding round closure50% success